The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA

Therapeutic Innovation and Regulatory Science · Published 2026-06-27 · DOI 10.1007/s43441-026-01005-y

Authors (7)

Ling Tang, Songmei Xie, Lijia Yuan, Xiaowen Xu, Xing Ai, Tian Zhao, Zhimin Yang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Tang, L., Xie, S., Yuan, L., et al. (2026). The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA. Therapeutic Innovation and Regulatory Science. https://doi.org/10.1007/s43441-026-01005-y

Related articles

• Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Impacts of Random and Fixed Effect Models on Type I and Type II Errors in Bioequivalence Hypotheses in Crossover Trial Designs: A Comprehensive Simulation Study · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Trends and Regulatory Insights on Illicit Pharmaceutical and Cosmetic Imports: Evidence from Malaysia’s Operation Pangea 2020–2023 · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• How Digital Health Technologies have been Used to Support Regulatory Drug Approval · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Feasibility of a Monthly Morphine Milligram Equivalent Metric for Opioid Surveillance Using the National Claims Database of Japan: A Repeated Cross-Sectional Study in a Low-Consumption Setting · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Measuring Centralized Patient Outreach Recruitment Strategies and their Costs in Clinical Trials · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Arbitrated Indirect Treatment Comparisons · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now? · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Accelerating Global Access for Indication Extension Through Regulatory Reliance Pilot: The First Indication Extension Pilot in Oncology · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China · Therapeutic Innovation and Regulatory Science · 2026 · Same journal